InfuSystem - INFU Stock Forecast, Price & News

0 Wall Street analysts have issued 12 month price targets for InfuSystem's shares. Their INFU share price forecasts range from $22.00 to $22.00. On average, they anticipate the company's stock price to reach $22.00 in the next twelve months. This suggests a possible upside of 125.4% from the stock's current price.
View analysts price targets for INFU or view top-rated stocks among Wall Street analysts.

InfuSystem's stock was trading at $9.30 on January 1st, 2023. Since then, INFU stock has increased by 4.9% and is now trading at $9.76.
View the best growth stocks for 2023 here.

InfuSystem saw a decrease in short interest during the month of December. As of December 30th, there was short interest totaling 99,700 shares, a decrease of 12.1% from the December 15th total of 113,400 shares. Based on an average trading volume of 37,100 shares, the short-interest ratio is currently 2.7 days. Currently, 0.6% of the shares of the company are sold short.
View InfuSystem's Short Interest.

InfuSystem Holdings, Inc. (NYSEAMERICAN:INFU) released its quarterly earnings results on Tuesday, November, 8th. The medical instruments supplier reported $0.02 earnings per share (EPS) for the quarter. The medical instruments supplier had revenue of $27.28 million for the quarter. InfuSystem had a net margin of 0.28% and a trailing twelve-month return on equity of 0.63%.

InfuSystem issued an update on its FY 2022 earnings guidance on Thursday, December, 8th. The company provided EPS guidance of for the period. The company issued revenue guidance of $112.00 million-$112.00 million, compared to the consensus revenue estimate of $112.67 million.

Based on aggregate information from My MarketBeat watchlists, some companies that other InfuSystem investors own include Macquarie Infrastructure (MIC), Ampio Pharmaceuticals (AMPE), Second Sight Medical Products (EYES), Navidea Biopharmaceuticals (NAVB), Otelco (OTEL), Pershing Gold (PGLC), Palatin Technologies (PTN), AgroFresh Solutions (AGFS), Advanced Micro Devices (AMD) and Digital Turbine (APPS).

InfuSystem trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "INFU."

InfuSystem's stock is owned by many different institutional and retail investors. Top institutional investors include Greenwood Capital Associates LLC (0.51%), Riverwater Partners LLC (0.25%), ARS Investment Partners LLC (0.19%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Barry G Steele, Blueline Capital Partners Ii,, Carrie Lachance, Christopher R Sansone, Gregg Owen Lehman, Jeannine Sheehan, Kevin Whitman, Meridian Ohc Partners, Lp, Paul Andrew Gendron, Richard Dilorio, Scott Shuda and Thomas Mark Ruiz.
View institutional ownership trends.

Shares of INFU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of INFU stock can currently be purchased for approximately $9.76.

InfuSystem (NYSEAMERICAN:INFU) has a market capitalization of $201.64 million and generates $102.38 million in revenue each year. The medical instruments supplier earns $1.42 million in net income (profit) each year or $0.01 on an earnings per share basis.

The company employs 394 workers across the globe.

InfuSystem's mailing address is 31700 Research Park Dr, MADISON HEIGHTS, MI 48071-4627, United States. The official website for the company is ir.infusystem.com. The medical instruments supplier can be reached via phone at (124) 291-1210 or via fax at 800-455-4338.